- Policy
- 1 ‘Soliris’ and 4 ‘Ultomiris’ cases seek prior approval
- by Lee, Hye-Kyung Feb 7, 2022 05:57am
- The 3 applications filed for preliminary approval of reimbursement to use ‘Ultomiris (ravulizumab)’ in new patients with paroxysmal nocturnal hemoglobinuria (PNH), and 1 application for re-deliberation were approved, and 2 cases of appeals that were filed were dismissed by Health Insurance Review and Assessment Service’s Healthcare Revie
- Policy
- Janssen Korea has obtained permission
- by Lee, Tak-Sun Feb 4, 2022 05:56am
- Janssen Korea has been approved by the MFDS for Pharmaceutical Consignment Permission for Manufacturing Business. This can be interpreted as part of the withdrawal of the Hyangnam plant. If Janssen Korea completely withdraws its Hyangnam plant, there will be no Janssen Korea plant facilities in Korea. The MFDS approved the "Manufacturing B
- Policy
- 45 generics of Dapagliflozin+Sitagliptin were approved
- by Lee, Tak-Sun Feb 3, 2022 05:57am
- Dapagliflozin+Sitaglipin from 45 companies, which can only be sold in September next year, has been approved. Analysts say that the number of licensed companies is increasing as Dongkoo and Daewon, which succeeded in developing products, start supplying generics. On the 28th, the MFDS approved 13 additional items of Dapagliflozin+Sitaglipti
- Policy
- Publicized discussion on PAH reimbursement bears fruit
- by Choi-sun Jan 28, 2022 05:57am
- The issue regarding reimbursement standards set for pulmonary arterial hypertension drugs finally bore fruit three years after experts in Korea including the Korean Society of Cardiology, Korean Pulmonary Hypertension Society, The Korean Society of Hypertension, and The Korean Academy of Tuberculosis and Respiratory Diseases publicized the i
- Policy
- Generics for Galvus will be listed next month
- by Kim, Jung-Ju Jan 28, 2022 05:57am
- Generics, which had patent disputes with Galvus, a DPP-4 inhibitor-based diabetes treatment, will be listed in earnest next month. This is because companies applied for a change in permit conditions and the MFDS approved it, making it possible to sell it immediately. According to the industry, the MOHW is pushing for a revision (proposal) of
- Policy
- MNCs ask to “Innovate new drug reimbursement environment"
- by Lee, Jeong-Hwan Jan 27, 2022 05:43am
- The key content of the policy proposal that representatives of multinational pharmaceutical companies with branches in Korea presented to the People Power Party’s election campaign committee was that the government should establish or improve the National Health Insurance and drug pricing system to encourage the use of highly effective but
- Policy
- PVA guidelines are about to be revised
- by Lee, Hye-Kyung Jan 27, 2022 05:43am
- The NHIS is internally reviewing a revision to the guidelines that includes a 100 → 90% change in the arithmetic average exclusion standard and a 15 → 2 billion won increase in the claim exclusion standard from this year's "Type Da" negotiations. NHIS' Senior director Lee Sangil said at the Korea Special Press Association briefing held o
- Policy
- The NHIS will begin research on improving the PVA system
- by Lee, Jeong-Hwan Jan 27, 2022 05:43am
- Health insurance authorities have announced plans to place an order for research services to evaluate the PVA system and prepare improvement measures. It is said that it will further specify the targets for drug cuts and health insurance financial savings through PVA as large items. However, she replied that it is difficult to accept immediat
- Policy
- PVA price reduction needs to be improved
- by Lee, Jeong-Hwan Jan 26, 2022 05:57am
- .There is a problem that the reduction rate of small items relatively increases compared to the financial impact by using the same formula for PVA negotiations. It was pointed out that the current PVA is operating too rigidly without reflecting the reality that medicines affect health insurance finances. Critics say that drugs that reduce hea
- Policy
- The presidential candidate's pledge to expand NIP is fierce
- by Lee, Jeong-Hwan Jan 26, 2022 05:57am
- The expansion of free HPV vaccine vaccination is spreading to a competition for pledges of presidential candidates between the ruling and opposition parties. As the ruling party candidate adopted the application of the NIP of the bivalent and HPV vaccine as a pledge, the opposition candidate is fiercely fighting, promising to support the
